1. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.
- Author
-
Tolaney, Sara M., Barry, William T., Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Partridge, Ann H., Hao Guo, Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., and Winer, Eric P.
- Subjects
- *
BREAST cancer treatment , *PACLITAXEL , *TRASTUZUMAB , *ADJUVANT treatment of cancer , *HER2 protein , *CANCER relapse , *DRUG side effects , *DRUG efficacy - Abstract
The article discusses a study which examined the treatment of human epidermal growth factor receptor type 2 (HER2)-positive breast cancer using adjuvant paclitaxel and trastuzumab. Topics discussed include the risk of early cancer recurrence, effectiveness and adverse events associated with the adjuvant therapy, and the rate of survival free from the disease.
- Published
- 2015
- Full Text
- View/download PDF